北京时间2026年1月22日，北京中喜文化传媒有限公司向美国证券交易委员会重新递交了上市申请，募资额大幅提升至约1875万美元，这标志着中概股赴美 上市的融资策略正在发生微妙变化。 2026年1月23日，搜狐报道称，中喜文化重新向美国SEC递交上市申请，拟以每股4至5美元发行375万股。而在此前的招股书中，该公司仅计划发行125万 股。 中喜文化的策略转变并非孤例。自2025年以来，美国市场对中国企业的态度发生了深刻变化，赴美上市规则正在全面收紧。 截至2025年上半年，中喜文化营收为1676万美元，净利润238万美元，主要股东包括冯彬和何晓云等人。其业务范围横跨传统电视节目发行和智能设备投屏 广告代理。 中喜文化并非唯一在2025年下半年调整IPO策略的中国企业。东方财富网报道称，当年6月13日以来，共有金特安、中喜文化、网塑科技等11家中企更新了 招股书。 从这些企业的募资规模看，多集中在500万至1500万美元区间。值得注意的是，当时中喜文化仍计划发行125万股，募资500万至625万美元。 这一波中概股赴美上市潮与2024年形成了鲜明对比。富途发布的2025年上半年IPO报告指出，2024年中国企业赴 ...

（来源：中国吉林网） 转自：中国吉林网 一是全力促进就业增收，筑牢民生保障底线。持续深化"两找一服务"工程，扎实实施青年就业启航专项 计划，精准拓宽高校毕业生、农民工等重点群体就业增收渠道，力争实现城镇新增就业8000人以上，农 村劳动力转移就业5.5万人以上，让群众就业更稳定、收入更可观。 2026年作为"十五五"规划开局之年，意义深远。刚刚落幕的省委经济工作会议，为全省新一年经济工作 擘画了清晰蓝图。白山市迅速锚定会议部署，聚焦高质量发展核心主题，真抓实干、笃定前行。近日， 白山市委副书记、市长王雪峰接受专访，他表示，省委经济工作会议明确了八方面重点任务，目标积极 务实、措施切实可行。其中构建特色现代化产业体系、加快美丽吉林建设等工作部署与白山实际高度契 合，为白山高质量发展指明了方向、提供了遵循，"我们将立足白山禀赋、结合发展实际，全力抓好会 议精神的落地生根、开花结果。" 回顾2025年，白山经济运行稳中向好，总投资117亿元的靖宇抽水蓄能电站开工建设，实现了百亿元项 目建设的突破。沈白高铁、G331沿边开放旅游大通道双线开通，文旅市场火爆出圈，全年接待国内游 客增长30%。医药健康、绿色食品、清洁能 ...

1月23日，天眼查融资历程显示，微睿科技（苏州）有限公司近日获得"A轮"融资，涉及融资金额近亿 人民币，投资机构为佰诺资本，弘德投资。 资料显示，微睿科技（苏州）有限公司法定代表人为聂西鹏，成立于2021年，位于苏州市，是一家以从 事医药制造业为主的企业。企业注册资本725.58万人民币，并已于2026年完成了A轮，交易金额近亿人 民币。 通过天眼查大数据分析，微睿科技（苏州）有限公司知识产权方面有商标信息1条，专利信息37条，此 外企业还拥有行政许可29个。 天眼查信息显示，微睿科技（苏州）有限公司的股东为：聂西鹏、苏州同舟见著企业管理合伙企业（有 限合伙）、扬州佰诺泽申创业投资合伙企业（有限合伙）、苏州弘德禾顺创业投资合伙企业（有限合 伙）、苏州同帆知微企业管理合伙企业（有限合伙）。 来源：市场资讯 ...

Core Viewpoint - Furuike Medical (300049.SZ) has disclosed its performance forecast for 2025, expecting a net profit attributable to shareholders of between 135 million to 164 million yuan, representing a year-on-year growth of 19.17% to 44.77% [1] Financial Performance - The company anticipates a net profit after deducting non-recurring gains and losses to be between 127 million to 166 million yuan, indicating a year-on-year increase of 7.89% to 41.02% [1]

Core Viewpoint - Zhongzhu Medical Holdings Co., Ltd. expects a net profit loss of 100 million to 150 million yuan for the year, with a loss of 110 million to 160 million yuan after excluding non-recurring gains and losses [1][4]. Group 1: Reasons for Loss - The anticipated loss is primarily due to two factors: the impact of the real estate market environment leading to a decline in property prices, resulting in significant asset impairment losses from commercial assets and substantial bad debt provisions for other receivables from joint ventures in commercial real estate projects [4]. - Additionally, the Beijing Loyal Oncology Hospital project has been unable to operate normally, leading to losses, and the company is currently executing a court ruling for its vacating [5]. Group 2: Company Background - Zhongzhu Medical was listed on the Shanghai Stock Exchange in May 2001, with its main business activities including pharmaceutical manufacturing, medical services, medical devices, and real estate [5]. - Zhongzhu Jun Tian (Beijing) Medical Technology Co., Ltd. is a subsidiary of Zhongzhu Medical and is the parent company of Beijing Loyal Oncology Hospital, which has been in a state of pending operation due to disputes over lease contracts and construction contracts since October 2022 [5].

Core Viewpoint - Company ST Zhongzhu (600568) expects a net loss attributable to shareholders of 1 billion to 1.5 billion yuan for the year 2025, an improvement from a loss of 6.2 billion yuan in the previous year [4] Financial Performance - The forecasted net profit loss for 2025 is between 1 billion and 1.5 billion yuan, while the non-recurring net profit loss is expected to be between 1.1 billion and 1.6 billion yuan, compared to a loss of 6.24 billion yuan in the previous year [4] - Historical net profit and non-recurring net profit figures show a consistent decline, with the company reporting a net loss of 6.2 billion yuan in 2023 and 7.99 billion yuan in 2022 [15] - The company's price-to-book ratio (LF) is approximately 3.16 times, and the price-to-sales ratio (TTM) is about 9.5 times based on the latest closing price [4] Business Operations - The company's main business areas include pharmaceutical manufacturing, medical services, medical devices, and real estate [14] - The decline in performance is attributed to the impact of the real estate market environment, leading to a decrease in property prices and significant asset impairment losses from commercial assets [14] - The Beijing Loyal Oncology Hospital project has incurred losses due to its inability to operate normally, and the company is currently executing a court ruling for its vacating [14]

Group 1 - The China International Import Expo (CIIE) has become a significant platform for global companies to access the Chinese market, with a record number of participating enterprises and an intention to achieve over $80 billion in transactions during the eighth edition of the expo [12][11][10] - Romania's REPUBLIKA sunflower oil has gained attention as a star product in the Chinese market, showcasing successful bilateral cooperation between China and Romania [5][1] - Belarusian dessert manufacturer "Vitba" has been actively investing in the Chinese market, leveraging the rapid growth of e-commerce and participating in major trade events like CIIE to enhance market presence [5][6] Group 2 - The eighth CIIE has introduced a dedicated section for products from least developed countries, attracting 163 companies, a 23.5% increase year-on-year, highlighting China's commitment to supporting global southern economies [17] - The Chinese government aims to balance trade development and enhance import facilitation through various platforms, including CIIE, to better meet industrial and consumer needs [11][16] - The participation of 125 Canadian companies in the eighth CIIE marks a historical high, reflecting the strong trade relationship between China and Canada, with bilateral trade reaching $10 billion in the first 11 months of 2025 [24]

Core Viewpoint - The report highlights the performance of the China Europe Medical Health Mixed Fund managed by Ge Lan and Zhao Lei, indicating a decline in total fund size and negative returns compared to benchmarks [1][4]. Fund Performance - As of December 31, 2025, the total size of the funds managed by Ge Lan decreased from 43.544 billion to 35.389 billion yuan [1]. - The A-class share of the China Europe Medical Health Mixed Fund recorded a net value growth rate of -14.81%, while the C-class share saw a decline of -14.98%, both underperforming the benchmark return of -8.21% [1][3]. Holdings Overview - The top ten holdings of the China Europe Medical Health Fund include WuXi AppTec, Heng Rui Medicine, and Kanglong Chemical, with notable increases in holdings for Hai Si Ke and Tai Ge Medicine, while reductions were seen in stocks like Ke Lun Pharmaceutical and Xin Li Tai [1][2]. Market Context - In Q4 2025, the CSI Pharmaceutical Index fell by 12.7%, underperforming the CSI 300 Index, which declined by only 0.2%. The report notes significant differentiation within sub-sectors, with innovative industries experiencing corrections while traditional Chinese medicine and pharmaceutical commerce remained relatively stable [3]. Future Outlook - Looking ahead to Q1 2026, improvements in global liquidity are expected to boost investment and financing in innovative pharmaceuticals, supported by domestic policy enhancements. The innovative drug and device industry is anticipated to maintain a high level of activity, with several key domestic drugs approaching critical data readouts [4][5]. - The report suggests that the pharmaceutical sector may continue to experience structural trends due to macroeconomic improvements, supportive industry policies, and ongoing innovation, with investment opportunities focusing on the progress of innovative drug and device exports, domestic substitution in equipment, and recovery in consumer healthcare demand [5].

Core Viewpoint - The report highlights the performance of the China Europe Medical Health Mixed Fund, managed by Ge Lan and Zhao Lei, indicating a decline in total fund size and negative returns compared to benchmarks for the fourth quarter of 2025 [1][4]. Fund Performance - As of December 31, 2025, the total size of funds managed by Ge Lan decreased from 43.544 billion to 35.389 billion yuan [1]. - The net value growth rate for Class A shares of the China Europe Medical Health Mixed Fund was -14.81%, while the benchmark return was -8.21% [1]. - Class C shares experienced a net value growth rate of -14.98%, also underperforming the benchmark [1]. Holdings Overview - The top ten holdings of the China Europe Medical Health Mixed Fund include WuXi AppTec, Heng Rui Medicine, and Kanglong Chemical, with notable increases in holdings for Hai Si Ke and Tai Ge Medicine, while reductions were seen in stocks like Ke Lun Pharmaceutical and Xin Li Tai [1][2]. - The largest holding, WuXi AppTec, accounted for 10.11% of the fund's net value, with a market value of approximately 2.724 billion yuan [2]. Market Context - The CSI Medical Index fell by 12.7% in the fourth quarter of 2025, underperforming the Shanghai and Shenzhen 300 Index, which declined by only 0.2% [3]. - There was significant differentiation within sub-sectors, with the innovative industry chain entering a correction phase after previous gains, while traditional Chinese medicine and pharmaceutical commerce showed relative stability [3]. Future Outlook - Looking ahead to the first quarter of 2026, improvements in global liquidity are expected to boost investment and financing in innovative drugs, supported by domestic policy enhancements [4]. - The innovative drug and medical device industry chain is anticipated to maintain high levels of activity, with several key domestic drugs approaching critical data readout points [5]. - The CXO sector is expected to benefit from a recovery in biotechnology financing, leading to improved order conditions [5]. - The pharmaceutical sector is projected to experience structural trends driven by macroeconomic improvements, supportive industry policies, and ongoing innovation [5].

Group 1 - The core point of the announcement is that King活医药 Group plans to acquire a well-known pharmaceutical company in Hong Kong for a cash consideration of HKD 66.4368 million, which will enhance its market presence and leverage the target company's brand influence for further expansion [1][2] - The acquisition price consists of HKD 41.5 million for the target company's core business and production equipment, and HKD 24.9368 million for real estate assets [1] - The chairman of King活医药 emphasized that this acquisition is a key move to enhance the health industry chain and global strategy, aligning with the company's extensive distribution network across 34 provinces and regions [2][3] Group 2 - The memorandum stipulates that King活医药 will pay a deposit of HKD 3.32184 million within five working days, which does not constitute a significant transaction under Hong Kong Stock Exchange rules [2] - Industry analysts believe that this acquisition will enrich the company's brand portfolio and strengthen its market position in Hong Kong and Macau, while also facilitating broader international market outreach [3] - The acquisition is seen as a strategic move to fill gaps in the company's pharmaceutical manufacturing capabilities and support its long-term goal of becoming a globally influential health industry platform [3]